Cytosorbents Crp - Asset Resilience Ratio
Cytosorbents Crp (CTSO) has an Asset Resilience Ratio of 0.00% as of September 2018. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read CTSO total debt and obligations for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2008–2017)
This chart shows how Cytosorbents Crp's Asset Resilience Ratio has changed over time. See CTSO net asset value for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Cytosorbents Crp's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Cytosorbents Crp market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Cytosorbents Crp maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Cytosorbents Crp Industry Peers by Asset Resilience Ratio
Compare Cytosorbents Crp's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
INKON Life Technology Co Ltd
SHE:300143 |
Medical Devices | 3.37% |
|
CareRay Digital Medical Technology Co Ltd
SHG:688607 |
Medical Devices | 16.21% |
|
Senseonics Holdings, Inc. Common Stock
NYSE MKT:SENS |
Medical Devices | 54.67% |
|
Universus Photo Imagings Limited
NSE:UNIVPHOTO |
Medical Devices | 30.97% |
|
HansBiomed Corporation
KQ:042520 |
Medical Devices | 9.13% |
|
Aligned Genetics Inc
KQ:238120 |
Medical Devices | 2.22% |
|
Heramed Ltd
AU:HMD |
Medical Devices | 0.83% |
|
Acarix A/S
ST:ACARIX |
Medical Devices | 37.81% |
Annual Asset Resilience Ratio for Cytosorbents Crp (2008–2017)
The table below shows the annual Asset Resilience Ratio data for Cytosorbents Crp.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2017-12-31 | 0.00% | $0.00 | $24.10 Million | -- |
| 2016-12-31 | 0.00% | $0.00 | $9.69 Million | -- |
| 2015-12-31 | 19.48% | $2.19 Million | $11.25 Million | -3.49pp |
| 2014-12-31 | 22.97% | $1.95 Million | $8.47 Million | -- |
| 2013-12-31 | 0.00% | $0.00 | $4.05 Million | -- |
| 2012-12-31 | 0.00% | $0.00 | $3.34 Million | -- |
| 2011-12-31 | 0.00% | $0.00 | $2.12 Million | -- |
| 2009-12-31 | 8.92% | $199.61K | $2.24 Million | +3.02pp |
| 2008-12-31 | 5.89% | $199.61K | $3.39 Million | -- |
About Cytosorbents Crp
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. The company's flagship product is CytoSorb, an extracorporeal blood purification cartridge for the treatment of massive inflamm… Read more